Nasdaq Stockholm´s listing committee has today announced that it considers that SynAct Pharma AB (“SynAct” or the “Company”) meets the applicable listing requirements and that they will approve the application for admission to trading of the Company’s shares in Nasdaq Stockholm Main Market subject to customary conditions being met, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the fulfilment of the distribution requirement for the Company’s shares. The first day of trading on Nasdaq Stockholm is expected to be Tuesday July 12, 2022, and the last day of trading on Spotlight Stock Market is expected to be Monday July 11, 2022.
The first day of trading on Nasdaq Stockholm is expected to be July 12, 2022. Due to the listing, SynAct will be de-listed from Spotlight Stock Market and the last day of trading on Spotlight Stock Market is expected to be July 11, 2022. Shareholders of SynAct will not need to take any actions in connection with the admission to trading on Nasdaq Stockholm.
A listing of the Company’s shares on Nasdaq Stockholm is an important step in SynAct’s continued development and gives the Company further access to the Swedish and international capital markets. SynAct has been listed on Spotlight Stock Market since 2016, but the board of directors believes that the listing of the Company’s share on Nasdaq Stockholm will increase the conditions for broadening SynAct’s shareholder base and give the Company access to additional international and institutional investors, which is deemed to promote the Company’s continued development. Furthermore, the listing also carries a quality stamp for SynAct and its operations.
“The fact that we have now been approved for listing on Nasdaq Stockholm’s main list means an important milestone for SynAct and our existing and new shareholders.”, says Jeppe Øvlesen, CEO.
About the list change
SynAct’s share will be traded in the Small Cap segment and will retain both its ticker (SYNACT) and ISIN code (SE0008241491). In connection with the list change, there will be no offering or issue of new shares.
Prospectus
SynAct is preparing a prospectus in connection with the admission to trading of the shares on Nasdaq Stockholm Main Market. The prospectus is expected to be approved and registered by the Swedish Financial Supervisory Authority and published on SynAct’s website, www.synactpharma.com, around July 8, 2022.
Advisors
Setterwalls Advokatbyrå AB is acting as legal advisor to SynAct in connection with the listing.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The information was submitted, through the agency of the contact person below, for publication at 3.30 p.m. CEST on June 28, 2022.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: [email protected]
Patrik Renblad
CFO, SynAct Pharma AB
Phone: +46 707 47 97 68
Mail: [email protected]